Introduction
This analysis examines the historical and forecast performance for Gilead in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Gilead Sciences: PharmaVitae Profile
Features and benefits
Gain insight into Gilead’s strategic outlook across the next 6 years
Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Gilead over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company’s prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
Benchmark Gilead’s performance against key rivals in the prescription pharmaceutical sector
Assess the effects of the patent expiry of one of the components of Atripla on the company
See how the launch of two new products, Truvada + rilpivirine and the Quad pill, will generate new growth for the company
Assess the effects of the patent expiry of one of the components of Atripla on the company
See how the launch of two new products, Truvada + rilpivirine and the Quad pill, will generate new growth for the company
